This study will assess if administration of Niagen (nicotinamide riboside, or NR) can reduce viral burden and inflammation in mouse and hamster models of COVID-19.
ChromaDex's patent-protected NR is a unique nutrient that supports cellular energy production and healthy mitochondrial function through efficient restoration of NAD+ levels.
The study is part of the ChromaDex External Research Program in which ChromaDex's NR ingredient and placebos are provided to researchers at no cost.
This joint study is designed to assess in mice and hamsters whether NR supplementation prior to infection can reduce progression of the infection either by limiting viral replication or modulating the inflammatory response, having a positive impact on disease severity and duration, as well as increasing survival.
A recent preclinical study showed SARS-CoV-2 infected cells suffer significant NAD+ depletion leading to disruption of innate anti-viral immune activity, while other preclinical data suggest that modulation of inflammasome activity in immune cells by NAD+ may be important in the severe inflammation observed in patients infected with COVID-19.
ChromaDex's Niagen is proven to effectively restore and maintain NAD+ levels.
The study will be conducted at the Rocky Mountain Labs of the NIH-NIAID.
This preclinical work builds on current trans-NIAID efforts to better understand SARS–CoV-2 pathogenesis, transmission, and mechanisms of protective immunity by expanding resources and activities that support rapid development of biomedical tools to more effectively combat this disease and pandemic.
ChromaDex scientists partner with universities and research institutions worldwide to discover, develop and create solutions to deliver the full potential of NAD and its impact on human health.
Its flagship ingredient, Niagen nicotinamide riboside, sold directly to consumers as Tru Niagen, is backed with clinical and scientific research, as well as extensive IP protection.
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer